Prostate

Localized

Treatment

Post Prostatectomy

High Risk

Low Risk

NRGGU003
Phase III Hypofractionated Post-Prostatectomy RT (HYPORT) vs Conventional Post-Prostatectomy RT (COPORT)
PI: Buyyounouski Stanford

Intact Prostate

Low Risk

PROS0065
Phase I/II High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer
PI: Buyyounouski Stanford

Diagnostic

Rising PSA Post Treatment

Can’t Have MRI

Ineligible for Study PROS0074 or 76 or Requested by Physician

Scheduled for Prostatectomy

Can’t Have MRI

PROS0075
Phase II/III 68Ga-PSMA PET/MRI for Detection of Regional Nodal and Distant Metastases in Prostate Ca
PI: Iagaru Stanford

PROS0076
Phase II/III 68Ga-PSMA PET/CT in Detection of Recurrent Prostate Cancer PI: Iagaru Stanford

PROS0077
Phase II 68Ga-RM2 PET/CT for Detection Metastases in Intermediate and High-Risk Prostate Cancer
PI: Iagaru Stanford

PROS0083
Phase x [f24-4818F]-DCFPyL PET/CT in Eval w/Biochem Recurrence of ProstateCA & Non-Contributory CTScans
PI: Iagaru Stanford

PROS0074
Phase II/III 68Ga-RM2 PET/MRI in Eval w/Biochem Recurrence of Prostate CA & Non-Contributory CT Scans
PI: Iagaru Stanford

NRGGU002
Phase II-III Adjuvant RT & AndrogenDeprivation after Radical Prostatectomy +/- Adjuvant Docetaxel
PI: Buyyounouski Pending

PROS0067
Focal MR-Guided Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions
PI: Sonn Insightec Inc.

PROS0087
Focal MR-Guided Ultrasound Therapy of Localized Intermediate Risk Prostate Lesions
PI: Buyyounouski NRG

PROS0087
Focal MR-Guided Ultrasound Therapy of Localized Intermediate Risk Prostate Lesions
PI: Buyyounouski NRG

KEY

Pending
Open for Enrollment
Observational Study
Optional Path
Trial Posting
Immunotherapy
Extension Study
Enrollment on Hold

Please mark up a copy using black ink and fax changes to 725-9204